<DOC>
	<DOCNO>NCT00126867</DOCNO>
	<brief_summary>Cancers colon rectum third common cancer Canadian male female . The initial therapy colorectal cancer surgery remove cancer nearby lymph gland . If cancer spread lymph glands high chance cancer come back . To reduce risk cancer recur , patient treat anticancer drug capecitabine . This study determine simple blood test predict patient risk develop side effect chemotherapy . In addition , participant study follow determine blood test predict patient cancer relapse .</brief_summary>
	<brief_title>Thymidylate Synthase Polymorphisms Predictor Toxicity Capecitabine Chemotherapy Colon Cancer Treatment</brief_title>
	<detailed_description>Hypothesis : Recently , thymidylate synthase gene 's promoter find polymorphic , variable number tandem repeat 28 base pair length . These polymorphism associate tumor response treatment fluoropyrimidines . The investigator hypothesize polymorphisms thymidylate synthase ( TS ) gene 's promoter region associate toxicity capecitabine treatment specifically development myelosuppression diarrhea . The investigator hypothesize polymorphism methylene tetrahydrofolate reductase ( MTHFR ) also associate toxicity efficacy capecitabine treatment . The investigator speculate MTHFR polymorphism become clinically significant stratify patient TS promoter polymorphism . Objectives : 1 . To determine polymorphisms thymidylate synthase 's promoter region associate development overall toxicity , diarrhea , neutropenia , mucositis patient treat capecitabine . 2 . To determine polymorphism methylene tetrahydrofolate reductase ( MTHFR ) associate development overall toxicity , diarrhea , neutropenia , mucositis patient treat capecitabine . Background Significance : Capecitabine potent antimetabolite currently accept adjuvant treatment colorectal cancer . As well , capecitabine use treat head neck cancer , breast cancer gastric cancer . In 1985 , Takeishi et al demonstrated thymidylate synthase 's gene satellite 5 ' untranslated region , consist 3 tandem repeat 28 base pair sequence . Horie et al demonstrated satellite polymorphic length due different number tandem repeat , 2 length polymorphism exist 2 tandem repeat 28 base pair ( 2R ) 3 tandem repeat 28 base pair ( 3R ) . Subsequent author demonstrate 4 repeat ( 4R ) , five repeat ( 5R ) nine repeat ( 9R ) . Kawakami et al demonstrate number tandem repeat affect TS gene translation . They show patient homozygous 3R allele higher TS protein level 2R/3R heterozygote . Using vitro expression 2R 3R gene demonstrate increased protein level due increase translational efficiency 3R RNA due increase 3R mRNA expression . These tandem repeat predictive response rate various cancer fluoropyrimidine cancer chemotherapy . Park et al show metastatic colorectal cancer patient treat capecitabine , response rate 14 % patient homozygous 3R repeat , 80 % patient homozygous 2R repeat . No prospective study examine patient 's TS genotype predict 5-FU toxicity . A polymorphism methylene tetrahydrofolate reductase 's ( MTHFR ) gene may also determine patient 's risk capecitabine toxicity . A polymorphism MTHFR exist position 677 , C T produce thermolabile rapidly degrade enzyme . TT homozygotes increase level methylene tetrahydrofolate . Methylene tetrahydrofolate stabilize bind 5FU thymidylate synthase complex TS , 5FU , methylene tetrahydrofolate refer ternary complex . I hypothesize increased stabilization TS 5FU due increase amount methylene tetrahydrofolate would lead increased capecitabine toxicity efficacy . No study examine TT homozygote increase response rate fluoropyrimidines increase toxicity . Dihydropyrimidine dehydrogenase ( DPD ) deficiency identify cause rare severe life threaten reaction fluoropyrimidines . The first case report Tuchman et al 27 year old woman undergone adjuvant chemotherapy cyclophosphamide , methotrexate , 5-fluoruracil develop severe neurological complication . Diasio et al report second case woman treat 5-fluoruracil breast cancer . A study Etienne et al raise question regard utility DPD activity alone predict patient risk fluoropyrimidine toxicity . They prospectively study 185 patient treat 5FU contain chemotherapy regimen . They find normal distribution DPD activity mean value 0.222 nmol/min/mg protein . They find correlation DPD activity 5FU toxicity . The investigator propose study effect two polymorphic enzyme capecitabine 's toxicity adjuvant colon cancer patient . It anticipate patient homozygous 2R/2R high rate overall toxicity , diarrhea , neutropenia mucositis 3R/3R homozygote . For MTHFR , anticipate TT homozygotes high rate overall toxicity , diarrhea , neutropenia , mucositis CC homozygotes . The effect MTHFR polymorphism capecitabine 's toxicity examine control thymidylate synthase genotype . Methods : Patients advise adjuvant chemotherapy colorectal cancer enrol . Patients treat standard dos capecitabine accord X-ACT study . Toxicities cycle one grade accord National Cancer Institute Common Toxicity Criteria Version 3.0 . Dose reduction cycle one record . Investigations : Prior start treatment patient provide 10 ml sample blood use obtain DNA white blood . Patients genotyped accord TS MTHFR genotype . Plasma bank determine DPD phenotype . Sample Size Calculation : The allele frequency 3R tandem repeat 0.6 2R tandem repeat 0.417 . In 100 patient therefore , I would expect 16 patient 2R/2R genotype , 48 2R/3R genotype 36 3R/3R genotype . It interesting note incidence grade 3/4 palmar plantar erythrodysesthesia diarrhea order 14 16 percent . A sample 104 patient would power 0.8 show statistically significant difference 40 % 2R/2R ( 60 % ) 3R/3R ( 20 % ) . Statistical Analysis : Associations TS genotype development grade 1/2 3/4 overall toxicity examine use chi square test , level significance 0.05 . Other toxicity interest , diarrhea , mucositis neutropenia , examine association TS genotype chi square test . Similar exploratory analysis do MTHFR phenotype .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>High risk Stage II III colon cancer Eastern Cooperative Oncology Group performance status ( ECOG P.S . ) O l No prior chemotherapy Complete tumor resection Candidate plan receive standard capecitabine Adequate bone marrow reserve Known DED deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>thymidylate synthase polymer</keyword>
	<keyword>rapecitabine</keyword>
	<keyword>adjuvant</keyword>
	<keyword>colon cancer</keyword>
	<keyword>toxicity</keyword>
	<keyword>Stage II colon cancer</keyword>
	<keyword>Stage III colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
</DOC>